Drawing for V

USPTO serial 79294440

V

Reviewed by CopyMark Law Group

Reg. 6504530Status 700Renewal
Filing date
Status date
Registration date
Oct 5, 2021
Examiner
CIANCI, RYAN MICHAEL
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with V?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Chemical additives for use in the manufacture of medical preparationsACTIVE
005Medical preparations for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical preparations for medical purposes for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; biological preparations for medical purposes for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical preparations for treating pulmonary diseases via inhalation; pharmaceutical preparations for the prevention and treatment of diseases and conditions of the respiratory and cardiovascular systemsACTIVE
010Medical apparatus and instruments, namely inhalers; drug delivery devices, namely inhalers; inhalers for medical use; metered dose inhalers for medical use; active dry powder inhalers for medical use; passive dry powder inhalers for medical use; nebulisers for respiration therapy; respirators for artificial respiration; component parts and fittings for all the aforesaid goodsACTIVE
042Scientific research relating to medical preparations and drug delivery devices; development and design medical preparations and drug delivery devices; analysis, and investigation in the form of testing of medical preparations and drug delivery devices; medical research; research relating to drug delivery devices; research relating to drug formulation; pharmaceutical developmentACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 8, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED
Apr 10, 2022FINOFINAL DECISION TRANSACTION PROCESSED BY IB
Mar 21, 2022FICSFINAL DISPOSITION NOTICE SENT TO IB
Mar 21, 2022FIMPFINAL DISPOSITION PROCESSED
Jan 5, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 5, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 20, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 20, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 19, 2021GPNXNOTIFICATION PROCESSED BY IB
Jun 30, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 30, 2021OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 30, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 15, 2021ALIEASSIGNED TO LIE
Jun 15, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jun 14, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jun 14, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 14, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 4, 2021RFNTREFUSAL PROCESSED BY IB
Dec 16, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 16, 2020RFRRREFUSAL PROCESSED BY MPU
Dec 3, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 2, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 24, 2020DOCKASSIGNED TO EXAMINER
Oct 3, 2020MAFRAPPLICATION FILING RECEIPT MAILED
Sep 29, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 24, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance